`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Paper No. 85
`Filed: July 27, 2018
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`ACRUX DDS PTY LTD., ACRUX LIMITED, and
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioners,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. and
`VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
`Patent Owner.
`
`
`
`Case: IPR2017-001901
`U.S. Patent No. 7,214,506
`
`
`
`PATENT OWNER’S UPDATED EXHIBIT LIST
`(as of July 27, 2018)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1 Case IPR2017-01429 has been joined with the instant proceeding.
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`Further to 37 C.F.R. § 42.63(e), Patent Owner Kaken Pharmaceutical Co.,
`
`Ltd. hereby submits a current listing of Kaken exhibits.
`
`EXHIBIT
`2001
`
`DESCRIPTION
`Declaration of Yoshiyuki Tatsumi (Japanese)
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`Research and Development Activity Report, dated
`May 28, 1999 (Japanese)
`
`Declaration of Yoshiyuki Tatsumi (English)
`
`Research and Development Activity Report, dated
`May 28, 1999 (English)
`
`Certificate of Translation: Declaration of Yoshiyuki
`Tatsumi
`
`Certificate of Translation: Research and Development
`Activity Report
`
`Richard K. Scher & Lisa M. Coppa, Advances in the
`Diagnosis and Treatment of Onychomycosis, 34 HOSP.
`MED. 11 (1998)
`
`Robert Baran et al., ONYCHOMYCOSIS: THE CURRENT
`APPROACH TO DIAGNOSIS AND THERAPY (1999)
`
`Markus Niewerth & Hans C. Korting, Management of
`Onychomycoses, 58 DRUGS 283 (1999)
`
`Boni E. Elewski, Onychomycosis: Pathogenesis, Diagnosis,
`and Management, 11 CLINICAL MICROBIOLOGY
`REVS. 415 (1998)
`
`Bradley D. Castellano, Chapter 23: Tinea Pedis and
`Onychomycosis: Overview of New Systemic Therapies, in
`RECONSTRUCTIVE SURGERY OF THE FOOT AND
`LEG (Nancy S. Vickers, ed., 1997)
`
`
`
`2
`
`
`
`EXHIBIT
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`DESCRIPTION
`Gouri V. Gupchup & Joel L. Zatz, Structural
`Characteristics and Permeability Properties of the Human
`Nail: A Review, 50 J. COSMETIC SCI. 363 (1999)
`
`Antonella Tosti & Bianca M. Piraccini, Chapter 18:
`Biology of Nails, in FITZPATRICK’S DERMATOLOGY IN
`GENERAL MEDICINE VOL. 1 (Irwin M. Freedberg et al., eds.,
`5th ed. 1999)
`
`Yoichi Kobayashi et al., Drug Permeation Through the
`Three Layers of the Human Nail Plate, 51 J. PHARMACY
`& PHARMACOLOGY 271 (1999)
`
`Sudaxshina Murdan, Drug Delivery to the Nail Following
`Topical Application, 236 INT’L J. PHARMACEUTICALS
`1 (2002)
`
`Yoshiyuki Tatsumi et al., Therapeutic Efficacy of Topically
`Applied KP-103 Against Experimental Tinea Unguium in
`Guinea Pigs in Comparison with Amorolfine and
`Terbinafine, 46 ANTIMICROBIAL AGENTS &
`CHEMOTHERAPY 3797 (2002)
`
`James Q. Del Rosso, The Role of Topical Antifungal
`Therapy for Onychomycosis and the Emergence of Newer
`Agents, 7 J. CLINICAL & AESTHETIC DERMATOLOGY
`10 (2014)
`
`Brian McCurdy, The Top Ten Innovations in Podiatry, 26
`PODIATRY TODAY 1 (2013), http://www.podiatrytoday
`.com/top-ten-innovations- podiatry-1
`
`Kenneth A. Walters et al., Physicochemical
`Characterization of the Human Nail: Solvent Effects on the
`Permeation of Homologous Alcohols, 37 J. OF
`PHARMACY & PHARMACOLOGY 771 (1985)
`
`
`
`3
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`DESCRIPTION
`Kenneth A. Walters et al., Physicochemical
`Characterization of the Human Nail: Permeation Pattern
`for Water and the Homologous Alcohols and Differences
`with Respect to the Stratum Corneum, 35 JOURNAL OF
`PHARMACY & PHARMACOLOGY 28 (1983)
`
`Kenneth A. Walters, Chapter 22: Ungual Formulations:
`Topical Treatment of Nail Diseases, in TREATMENT OF
`DRY SKIN SYNDROME: THE ART AND SCIENCE OF
`MOISTURIZERS (Marie Lodén & Howard I. Maibach,
`eds., 2012)
`
`Acrux Files New Intellectual Property Application for
`Onychomycosis Product, ACRUX (Nov. 2, 2016),
`http://www.asx.com.au/asxpdf/20161102/pdf/43cldkvypcq
`j00.pdf
`
`Declaration of Barbara R. Rudolph, Ph.D. in Support of
`Patent Owner’s Unopposed Motion for Pro Hac Vice
`Admission
`
`Second Declaration of Yoshiyuki Tatsumi (Japanese)
`
`Second Declaration of Yoshiyuki Tatsumi (English)
`
`Certificate of Translation: Second Declaration of Yoshiyuki
`Tatsumi
`
`Declaration of Boni E. Elewski, M.D.
`
`Declaration of Vince Thomas
`
`Robert Langreth & Matthew Herper, Pill Pushers: How the
`drug industry abandoned science for salesmanship,
`FORBES, May 8, 2006, at 94
`
`Laboratory Notebook 1992-1993 (Japanese)
`
`Laboratory Notebook 1992-1993 (English)
`
`EXHIBIT
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`2028
`
`2029
`
`2030
`
`2031
`
`
`
`4
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2032
`
`DESCRIPTION
`Certificate of Translation: Laboratory Notebook 1992-1993
`
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`2039
`
`2040
`
`2041
`
`2042
`
`2043
`
`2044
`
`2045
`
`Laboratory Notebook 1993 (Japanese)
`
`Laboratory Notebook 1993 (English)
`
`Certificate of Translation: Laboratory Notebook 1993
`
`Abstract F790 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy
`held on September 15-18, 1996 (1996) with cover sheet
`
`Abstract F792 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy
`held on September 15-18, 1996 (1996) with cover sheet
`
`Abstract F793 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy
`held on September 15-18, 1996 (1996) with cover sheet
`
`Research and Development Activity Report, dated May 28,
`1999 (Japanese)
`
`Corrected Research and Development Activity Report,
`dated May 28, 1999 (English)
`
`Certificate of Translation: Corrected Research and
`Development Activity Report, dated May 28, 1999
`
`May 21, 1999 Data Entitled “Effectiveness on guinea pig
`onychomycosis” (Japanese)
`
`May 21, 1999 Data Entitled “Effectiveness on guinea pig
`onychomycosis” (English)
`
`Certificate of Translation: May 21, 1999 Data Entitled
`“Effectiveness on guinea pig onychomycosis”
`
`Tatsumi Research and Development Activity Report, dated
`May 26, 1999 (Japanese)
`
`
`
`5
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2046
`
`DESCRIPTION
`Tatsumi Research and Development Activity Report, dated
`May 26, 1999 (English)
`
`2047
`
`2048
`
`2049
`
`2050
`
`2051
`
`2052
`
`2053
`
`2054
`
`2055
`
`2056
`
`Certificate of Translation: Tatsumi Research and
`Development Activity Report, dated May 26, 1999
`
`Xiaoying Hui et al., In Vitro Penetration of a Novel
`Oxaborole Antifungal (AN2690) into the Human Nail Plate,
`96 J. PHARM. SCIENCES 2622 (2007)
`
`Keita Sugiura et al., The Low Keratin Affinity of
`Efinaconazole Contributes to Its Nail Penetration and
`Fungicidal Activity in Topical Onychomycosis Treatment,
`58 ANTIMICROB. AGENTS CHEMOTHER. 3837 (2014)
`
`Transcript of Deposition of Kenneth Walters
`
`Rania Elkeeb et al., Transungual Drug Delivery: Current
`Status, 384 INT’L J. PHARMACEUTICALS 1 (2010)
`
`B.E. Elewski et al., Efficacy, safety and tolerability of
`topical terbinafine nail solution in patients with mild-to-
`moderate toenail onychomycosis: results from three
`randomized studies using double-blind vehicle-controlled
`and open-label active-controlled designs, 27 JEADV 287
`(2013)
`
`Penlac® Label, FDA, Approved Dec. 17, 1999
`
`Jublia® Label, FDA, Approved Jun. 6, 2014
`
`Shari Lipner & Richard Scher, Efinaconazole in the
`Treatment of Onychomycosis, 8 INFECTION AND DRUG
`RESISTANCE 163 (2015)
`
`Mahmoud Ghannoum & Nancy Isham, Fungal Nail
`Infections (Onychomycosis): A Never-Ending Story? 10
`PLOS PATHOGENS 1 (2014)
`
`
`
`6
`
`
`
`EXHIBIT
`2057
`
`2058
`
`2059
`
`2060
`
`2061
`
`2062
`
`2063
`
`2064
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`DESCRIPTION
`Mustafa Elsayed, Development of Topical Therapeutics for
`Management of Onychomycosis and Other Nail Disorders:
`A Pharmaceutical Perspective, 199 J. CONTROLLED
`RELEASE 132 (2015)
`
`David C. Holzman, Freely Diffusing Topical Antifungal
`Agent Fixes Infected Toenails, 9 MICROBE 267 (2014)
`
`Press Release, The Galien Foundation Announces 2015
`Prix Galien USA Nominees for “Best Biotechnology
`Product,” “Best Pharmaceutical Agent,” and “Best
`Medical Technology” (Aug. 6, 2015), available at
`http://www.prnewswire.com/news-releases/the-galien-
`foundation-announces-2015-prix-galien-usa-nominees-for-
`best-biotechnology-product-best-pharmaceutical-agent-and-
`best-medical-technology-300124894.html (last visited Aug.
`1, 2017).
`
`Phillip Rodgers & Mary Bassler, Treating Onychomycosis,
`63 AM. FAM. PHYSICIAN 663 (2001)
`
`RESERVED
`
`Elaine Fuchs, Keratins and the Skin, 11 ANNUAL REV. CELL
`DEV. BIOL. 123 (1995)
`
`Superbrands: A Special Report, Brandweek (Jun. 21,
`2004), http://brandautopsy.typepad.com/superbrands_2004
`_brandweek.pdf (last visited Aug. 1, 2017)
`
`Securities and Exchange Commission Form 20-F for
`Aventis for the fiscal year ended Dec. 31, 2003,
`https://www.sec.gov/ Archives/edgar/data/807198/
`000104746904006848/a2128888z20-f.htm (last visited
`Aug. 1, 2017)
`
`
`
`7
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2065
`
`DESCRIPTION
`Daniéle Debruyne & Antoine Coquerel, Pharmacokinetics
`of Antifungal Agents in Onychomycoses, 40 CLIN.
`PHARMACOKINET. 441 (2001)
`
`2066
`
`2067
`
`2068
`
`2069
`
`2070
`
`2071
`
`2072
`
`2073
`
`Vagistat® Label, FDA, Approved Feb. 6, 1997
`
`Monistat® Label, FDA, Approved Mar. 30, 1998
`
`Gyne-Lotrimin® Label, FDA, Approved Nov. 24, 1998
`
`Jill Ferrari, Fungal Toenail Infections, 12 CLINICAL
`EVIDENCE 1 (2008)
`
`Yoshiki Matsuda, et al., Efficacy Coefficients Determined
`Using Nail Permeability and Antifungal Activity in Keratin-
`Containing Media are Useful for Predicting Clinical
`Efficacies of Topical Drugs for Onychomycosis, 11 PLOS
`ONE 1 (2016)
`
`Chris G. Adigun, Onychomycosis (Tinea Unguium), Merck
`Manual, available at https://www.merckmanuals.com/
`professional/dermatologic-disorders/nail-
`disorders/onychomycosis (last visited Aug. 1, 2017)
`
`Dyanne P. Westerberg & Michael J. Voyack,
`Onychomycosis: Current Trends in Diagnosis and
`Treatment, 88 AMERICAN FAMILY PHYSICIAN 762 (2013)
`
`Boni Elewski et al., Efficacy and safety of tavaborole
`topical solution, 5%, a novel boron-based antifungal agent,
`for the treatment of toenail onychomycosis: Results from 2
`randomized phase-III studies, 73 J. AMERICAN ACAD.
`DERMATOL. 62 (2015)
`
`2074
`
`Boni Elewski, Tinea capitis: A current perspective, 42 J.
`AM. ACAD. DERMATOL. 1 (2000)
`
`
`
`8
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2075
`
`2076
`
`2077
`
`2078
`
`2079
`
`2080
`
`2081
`
`2082
`
`DESCRIPTION
`
`Chapter 206: Superficial Fungal Infection:
`Dermatophytosis, Tinea Nigra, Piedra; Chapter 247:
`Topical Antifungal Agents; and Chapter 260: Oral
`Antifungal Agents, in FITZPATRICK’S DERMATOLOGY IN
`GENERAL MEDICINE VOL. 11 (Irwin M. Freedberg et al.,
`eds., 5th ed. 1999)
`
`Jacques F.G.M Meis & Paul E. Verweij, Current
`Management of Fungal Infections, 61 Supp. 1 DRUGS 13
`(2001)
`
`Piet De Doncker et al., Antifungal Pulse Therapy for
`Onychomycosis, 132 ARCH. DERMATOL. 34 (1996)
`
`R. Baran et al., A New Classification of Onychomycosis,
`139 BRITISH J. OF DERMATOL. 567 (1998)
`
`Greg Gargiulo, Onychomycosis Remains a Major Clinical
`Challenge (Nov. 2014), available at
`http://lermagazine.com/article/onychomycosis-remains-a-
`major-clinical-challenge (last visited Aug. 1, 2017)
`
`Anahad O’Connor, Ask Well: Leaving Nail Fungus
`Untreated, The New York Times online (Oct. 11, 2013),
`available at
`https://well.blogs.nytimes.com/2013/10/11/ask-well-
`leaving-nail-fungus-untreated/ (last visited Aug. 1, 2017)
`
`Jennifer Acosta Scott, The Dangers of Ignoring Toenail
`Fungal Infections (Sep. 8, 2014), available at
`http://www.everydayhealth.com/hs/toenail-fungal-
`infection-guide/dangers-of-ignoring-toenail-fungal-
`infections/ (last visited Aug. 1, 2017)
`
`E. Gauthier et al., A Novel Method to Study Drug
`Permeation Through the Human Nail Plate, 7A
`PERSPECTIVES IN PERCUTANEOUS PENETRATION 69 (2000)
`
`
`
`9
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`DESCRIPTION
`Darren M. Green et al., Chapter 28: Nail Delivery, in
`Modified-Release Drug Delivery Technology, Second Ed.,
`Vol. 2 (Michael J. Rathbone et al., eds., 2008)
`
`Aditya K. Gupta & Catherine Studholme, Update on
`Efinaconazole 10% Topical Solution of Onychomycosis, 21
`SKIN THERAPY LETTER 6 (2016)
`
`Aditya K. Gupta, Efinaconazole: A New Topical Treatment
`for Onychomycosis, 19 SKIN THERAPY LETTER 1 (2014)
`
`B.S. Barot et al., Drug Delivery to the Nail: Therapeutic
`Options and Challenges for Onychomycosis, 31 CRIT. REV.
`THER. DRUG CARRIER SYS. 459 (2014) (abstract)
`
`Nail Fungus Treatment, Mayo Clinic, available at
`http://www.mayoclinic.org/diseases-conditions/nail-
`fungus/diagnosis-treatment/treatment/txc-20342485 (last
`visited Aug. 1, 2017)
`
`Kristine Hoffman, A Closer Look at a New Topical Option
`for Onychomycosis, Podiatry Today (Oct. 1, 2014),
`available at http://www.podiatrytoday.com/blogged/closer-
`look-new-topical-option-onychomycosis (last visited Aug.
`1, 2017)
`
`Warren Joseph et al., Onychomycosis and the Role of
`Topical Antifungals, Suppl. to Podiatry Today (Nov. 2013)
`
`Kaken Pharmaceuticals, Clenafin, available at
`http://www.kaken.co.jp/english/business/top12.html (last
`visited Aug. 1, 2017)
`
`Jublia® Website, available at http://www.jubliarx.com/ (last
`visited Aug. 1, 2017)
`
`EXHIBIT
`2083
`
`2084
`
`2085
`
`2086
`
`2087
`
`2088
`
`2089
`
`2090
`
`2091
`
`
`
`10
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`DESCRIPTION
`Press Release, Valeant Pharmaceuticals Announces FDA
`Approval of Jublia® for the Treatment of Onychomycosis,
`(Jun. 9, 2014), available at http://ir.valeant.com/news-
`releases/2014/09-06-2014
`
`Jublia® Commericial Market Comparison, Jan. 26, 2017
`(CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)
`Jublia® Monthly TRx, NRx Data for US 2017
`(CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)
`
`Jublia® Data dated May 31, 2017 (CONFIDENTIAL -
`PROTECTIVE ORDER MATERIAL)
`
`Protective Order
`
`Declaration of Ashley Winkler
`
`Jublia Sales (CONFIDENTIAL - PROTECTIVE ORDER
`MATERIAL)
`
`U.S. Onychomycosis Prescriptions (CONFIDENTIAL -
`PROTECTIVE ORDER MATERIAL)
`
`Evidentiary Declaration of Edward Shupenus – SERVED
`NOT FILED
`
`Second Evidentiary Declaration of Ashley Winkler –
`SERVED NOT FILED
`
`Evidentiary Declaration of Yoshiyuki Tatsumi, Ph.D.
`(Japanese) – SERVED NOT FILED
`
`Evidentiary Declaration of Yoshiyuki Tatsumi, Ph.D.
`(English) – SERVED NOT FILED
`
`Certificate of Translation: Evidentiary Declaration of
`Yoshiyuki Tatsumi, Ph.D. – SERVED NOT FILED
`
`EXHIBIT
`2092
`
`2093
`
`2094
`
`2095
`
`2096
`
`2097
`
`2098
`
`2099
`
`2100
`
`2101
`
`2102
`
`2103
`
`2104
`
`
`
`11
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2105
`
`DESCRIPTION
`Evidentiary Declaration of Boni E. Elewski, M.D. –
`SERVED NOT FILED
`
`2106
`
`2107
`
`2108
`
`2109
`
`2110
`
`2111
`
`2112
`
`2113
`
`2114
`
`2115
`
`2116
`
`Evidentiary Declaration of Vincent A. Thomas, CPA,
`CVA, CFF, ABV – SERVED NOT FILED
`
`Abstract F790 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy,
`September 15-18, 1996 (1996) – SERVED NOT FILED
`
`Abstract F792 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy,
`September 15-18, 1996 (1996) – SERVED NOT FILED
`
`Abstract F793 from Abstracts of the 36th Interscience
`Conference on Antimicrobial Agents and Chemotherapy,
`September 15-18, 1996 (1996) – SERVED NOT FILED
`
`Antifungal Sales Data (2014-2017) with Japanese
`(CONFIDENTIAL - PROTECTIVE ORDER MATERIAL)
`– SERVED NOT FILED
`
`English Translation of Japanese portions of Antifungal
`Sales Data (2014-2017)
`
`Certificate of English Translation of Japanese portions of
`Antifungal Sales Data (2014-2017)
`
`Evidentiary Declaration of Motonori Miyakawa (Japanese)
`
`Evidentiary Declaration of Motonori Miyakawa (English) –
`SERVED NOT FILED
`
`Certificate of Translation: Evidentiary Declaration of
`Motonori Miyakawa – SERVED NOT FILED
`
`Transcript of Deposition of John C. Staines, Jr. (November
`30, 2017) (REDACTED VERSION)
`
`
`
`12
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`EXHIBIT
`2116A
`
`DESCRIPTION
`Transcript of Deposition of John C. Staines, Jr. (November
`30, 2017) (CONFIDENTIAL - PROTECTIVE ORDER
`MATERIAL)
`
`2117
`
`2118
`
`2119
`
`2200
`
`2201
`
`2202
`
`2203
`
`Transcript of Deposition of Kenneth A. Walters, Ph.D.
`(December 6, 2017)
`
`Transcript of Deposition of Jeffrey M. Weinberg, M.D.
`(December 11, 2017)
`
`RESERVED
`
`Press Release, Antifungal Agent “Mentax” (Butenafine
`HCI) Approved by FDA, (Nov. 13, 1996), available at
`http://www.kaken.co.jp/english/en_release/
`en_nr19961113.html
`
`Maureen B. Jennings, et al., Study of Clinically Suspected
`Onychomycosis in a Podiatric Population, 92 JOURNAL OF
`THE AMERICAN PODIATRIC MEDICAL ASSOCIATION 327-30
`(2002)
`
`Email from Aydin Harston to Anthony Hartmann dated
`August 23, 2017
`
`Email correspondence between Parties and the Board (July
`12-20, 2018)
`
`Dated: July 27, 2018
`
`
`
`
`
`Respectfully submitted,
`
`
`By: /John D. Livingstone/
`John D. Livingstone, Reg. No. 59,613
`FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, LLP
`Lead Counsel for Patent Owner
`
`
`13
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`CERTIFICATE OF SERVICE
`
`The undersigned certifies that a copy of the foregoing Patent Owner’s
`
`Updated Exhibit List and Exhibit 2203 were served electronically via email on
`
`July 27, 2018, in their entirety on the following:
`
`E. Anthony Figg
`Aydin H. Harston
`Lisa N. Phillips
`Rothwell, Figg, Ernst & Manbeck, P.C.
`607 14th Street, N.W., Suite 800
`Washington, DC 20005
`efigg@rothwellfigg.com
`aharston@rothwellfigg.com
`lphillips@rothwellfigg.com
`litigationparalegals@rothwellfigg.com
`
`Teresa Stanek Rea
`Shannon M. Lentz
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Ave., NW
`Washington, DC 20004-2595
`trea@crowell.com
`slentz@crowell.com
`
`Tyler C. Liu
`Argentum Pharmaceuticals, LLC
`tliu@agpharm.com
`
`
`
`
`
`
`
`
`
`By: /John D. Livingstone/
`John D. Livingstone
`Reg. No. 59,613
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
